论文部分内容阅读
目的:探讨脑膜癌病的临床表现、影像学特征、脑脊液特点和预后。方法:回顾性分析2015年5月1日至2020年5月31日于河南省人民医院就诊的脑脊液细胞学证实的脑膜癌病患者的临床表现、脑脊液改变以及影像表现并进行随访，分析脑膜癌病预后的相关因素。结果:共纳入患者88例，其中男42例（47.7%）、女46例（52.3%），中位年龄59岁（28~78岁）；病理分型为肺癌58例（65.9%），胃癌13例（14.8%），乳腺癌7例（8.0%），黑色素瘤1例，食管癌1例，胆囊癌1例，肾癌1例，双源癌2例，不明来源4例。中位Karnofsky功能状态（KPS）评分50分。34例患者以神经系统症状为首诊。临床表现中，有73例（83.0%）头痛、63例（71.6%）恶心呕吐、37例（42.0%）精神行为异常、41例（46.6%）癫痫发作，23例（39.0%）颅神经受累，20例（33.9%）脊神经受累。61例（83.6%）的患者影像学呈阳性改变。87例患者完成了脑脊液细胞学检查，首次脑脊液细胞学阳性率90.8%，47例（54.7%）患者可见激活单核细胞。中位总生存期13.0（95%n CI：2.9~23.1）周，1年生存率19.1%。肺癌、KPS≥50分、应用酪氨酸激酶抑制剂（TKIs）、全脑放疗为利于预后的相关因素（均n P<0.05）。n 结论:脑膜癌病总体预后差，较好的身体状态、TKIs药物治疗、全脑放疗是利于患者预后的因素。“,”Objective:To describe the clinical manifestations, neuroimaging, cerebrospinal fluid(CSF) cytology and prognosis of Leptomeningeal metastases(LM).Methods:The clinical manifestations, imaging features and CSF cytology of LM patients admitted to Henan Provincial People′s Hospital from May 1, 2015 to May 31, 2020 were retrospectively analyzed. The overall survival (OS) was evaluated by the time from the diagnosis of LM to death.Results:A total of 88 patients with LM were enrolled in the study, and the median age was 59 years (range:28-78 years). There were 42 males (47.7%) and 46 females (52.3%). According to the pathological classification, it was lung cancer in 58 cases (65.9%), gastric cancer in 13 cases (14.8%), breast cancer in 7 cases (8.0%), melanoma in 1 case, esophageal cancer in 1 case, gallbladder cancer in 1 case, renal cell carcinoma in 1 case, double source cancer in 2 cases, and unknown source in 4 cases. The median Karnofsky Performance Scale (KPS) score was 50. LM was the initial manifestation of cancer in 34 patients. All patients had LM-related clinical symptoms, including headache in 73 cases (83.0%), nausea and vomiting in 63 cases (71.6%), abnormal physical and mental behaviors in 37 cases (42.0%), seizure in 41 cases (46.6%). Cranial nerve involvement was observed in 23 patients (39.0%) and spinal nerve involvement in 20(33.9%). There were 61 patients (83.6%) who showed neuroimaging features of LM. Tumor cells or atypical cells were found in 90.8% of patients for the first time, and activated monocytes in 47 cases (54.7%). The median OS was 13.0 weeks (95%n CI:2.9-23.1) with the 1-year survival rate of 19.1%. Univariate analysis of survival indicated that lung cancer, lower KPS score, tyrosine kinase inhibitors (TKIs) and whole brain radiotherapy were favorable predictors of survival (n P<0.05).n Conclusions:The overall prognosis of LM is poor. Good physical condition, TKIs treatment and whole brain radiotherapy might improve clinical outcomes of LM patients.